Maren Leifheit-Nestler1, Robert Große Siemer1, Kathrin Flasbart1, Beatrice Richter1, Felix Kirchhoff1, Wolfgang H Ziegler1, Michael Klintschar2, Jan U Becker3, Andreas Erbersdobler4, Christoph Aufricht5, Tomas Seeman6, Dagmar-Christiane Fischer7, Christian Faul8, Dieter Haffner1. 1. Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. 2. Institute for Forensic Medicine, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. 3. Institute of Pathology, University Hospital Cologne, Kerpener Str. 62, 50937 Cologne, Germany. 4. Institute of Pathology, University Hospital Rostock, Strempelstr. 14, 18055 Rostock, Germany. 5. Division of Pediatric Nephrology, University Children's Hospital Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. 6. Division of Pediatric Nephrology, University Children's Hospital Motol, V Uvalu 84, 15006, Prague, Czech Republic. 7. Department of Pediatrics, University Hospital Rostock, Ernst-Heydemann-Str. 8, 18057 Rostock, Germany. 8. Division of Nephrology and Hypertension, Department of Medicine, University of Miami Miller School of Medicine, 1580 NW 10th Avenue (R-762), Miami, FL 33136, USA.
Abstract
BACKGROUND: In chronic kidney disease (CKD), serum concentrations of fibroblast growth factor 23 (FGF23) increase progressively as glomerular filtration rate declines, while renal expression of the FGF23 coreceptor Klotho decreases. Elevated circulating FGF23 levels are strongly associated with mortality and with left ventricular hypertrophy (LVH), which is a major cause of cardiovascular death in CKD patients. The cardiac FGF23/FGF receptor (FGFR) system and its role in the development of LVH in humans have not been addressed previously. METHODS: We conducted a retrospective case-control study in 24 deceased patients with childhood-onset end-stage renal disease (dialysis: n = 17; transplanted: n = 7), and 24 age- and sex-matched control subjects. Myocardial autopsy samples of the left ventricle were evaluated for expression of endogenous FGF23, FGFR isoforms, Klotho, calcineurin and nuclear factor of activated T-cells (NFAT) by immunohistochemistry, immunofluorescence microscopy, qRT-PCR and western blotting. RESULTS: The majority of patients presented with LVH (67%). Human cardiomyocytes express full-length FGF23, and cardiac FGF23 is excessively high in patients with CKD. Enhanced myocardial expression of FGF23 in concert with Klotho deficiency strongly correlates with the presence of LVH. Cardiac FGF23 levels associate with time-averaged serum phosphate levels, up-regulation of FGFR4 and activation of the calcineurin-NFAT signaling pathway, an established mediator of cardiac remodelling and LVH. These changes are detected in patients on dialysis but not in those with a functioning kidney transplant. CONCLUSIONS: Our results indicate a strong association between LVH and enhanced expression levels of FGF23, FGFR4 and calcineurin, activation of NFAT and reduced levels of soluble Klotho in the myocardium of patients with CKD. These alterations are not observed in kidney transplant patients.
BACKGROUND: In chronic kidney disease (CKD), serum concentrations of fibroblast growth factor 23 (FGF23) increase progressively as glomerular filtration rate declines, while renal expression of the FGF23 coreceptor Klotho decreases. Elevated circulating FGF23 levels are strongly associated with mortality and with left ventricular hypertrophy (LVH), which is a major cause of cardiovascular death in CKDpatients. The cardiac FGF23/FGF receptor (FGFR) system and its role in the development of LVH in humans have not been addressed previously. METHODS: We conducted a retrospective case-control study in 24 deceased patients with childhood-onset end-stage renal disease (dialysis: n = 17; transplanted: n = 7), and 24 age- and sex-matched control subjects. Myocardial autopsy samples of the left ventricle were evaluated for expression of endogenous FGF23, FGFR isoforms, Klotho, calcineurin and nuclear factor of activated T-cells (NFAT) by immunohistochemistry, immunofluorescence microscopy, qRT-PCR and western blotting. RESULTS: The majority of patients presented with LVH (67%). Human cardiomyocytes express full-length FGF23, and cardiac FGF23 is excessively high in patients with CKD. Enhanced myocardial expression of FGF23 in concert with Klotho deficiency strongly correlates with the presence of LVH. Cardiac FGF23 levels associate with time-averaged serum phosphate levels, up-regulation of FGFR4 and activation of the calcineurin-NFAT signaling pathway, an established mediator of cardiac remodelling and LVH. These changes are detected in patients on dialysis but not in those with a functioning kidney transplant. CONCLUSIONS: Our results indicate a strong association between LVH and enhanced expression levels of FGF23, FGFR4 and calcineurin, activation of NFAT and reduced levels of soluble Klotho in the myocardium of patients with CKD. These alterations are not observed in kidney transplant patients.
Authors: Daniel Edmonston; Daniel Wojdyla; Rupal Mehta; Xuan Cai; Claudia Lora; Debbie Cohen; Raymond R Townsend; Jiang He; Alan S Go; John Kusek; Matthew R Weir; Tamara Isakova; Michael Pencina; Myles Wolf Journal: Am J Kidney Dis Date: 2019-08-21 Impact factor: 8.860
Authors: Ketaki N Mhatre; Paulina Wakula; Oliver Klein; Egbert Bisping; Jakob Völkl; Burkert Pieske; Frank R Heinzel Journal: Cell Mol Life Sci Date: 2018-07-30 Impact factor: 9.261
Authors: Olaya Hernández-Frías; Helena Gil-Peña; José M Pérez-Roldán; Susana González-Sanchez; Gema Ariceta; Sara Chocrón; Reyner Loza; Francisco de la Cerda Ojeda; Leire Madariaga; Inés Vergara; Marta Fernández-Fernández; Susana Ferrando-Monleón; Montserrat Antón-Gamero; Ángeles Fernández-Maseda; M Isabel Luis-Yanes; Fernando Santos Journal: Pediatr Nephrol Date: 2019-01-04 Impact factor: 3.714
Authors: Erica L Clinkenbeard; Megan L Noonan; Joseph C Thomas; Pu Ni; Julia M Hum; Mohammad Aref; Elizabeth A Swallow; Sharon M Moe; Matthew R Allen; Kenneth E White Journal: JCI Insight Date: 2019-02-21